PHIA Koninklijke Philips N.V.

Philips launches obstetrics monitoring solution to support clinicians and expectant mothers during COVID-19 pandemic

Philips launches obstetrics monitoring solution to support clinicians and expectant mothers during COVID-19 pandemic

June 12, 2020

  • Under new April 2020 FDA guidance [1], the Avalon CL Fetal and Maternal Pod and Patch are now available in the U.S., in addition to existing countries in Europe, Australia, New Zealand and Singapore, to support fetal and maternal monitoring
  • Integrated with Philips’ comprehensive obstetrical care portfolio, the new offering has the potential to reduce mother and clinician risk of exposure to COVID-19, in hospital and in the home
  • Solution complements Philips innovative Remote Patient Monitoring suite designed to transform care for at-risk populations

Amsterdam, the Netherlands –  (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced an addition to its remote patient monitoring suite supporting at-risk populations during the COVID-19 emergency. The new wireless Avalon CL Fetal and Maternal Pod and Patch aim to reduce unnecessary physical interactions between clinicians and patients, which is of particular importance during the COVID-19 pandemic. The patch is part of a broader innovative high-risk pregnancy solution which includes Philips perinatal analytics, and visualization software as well as an ultra-portable battery-operated fetal monitor. 

Up to half a million women may deliver their babies while infected with COVID-19 in 2020. Additionally, pregnant women who have not been diagnosed with COVID-19 are interested in ways they can minimize their time in a hospital to limit their exposure to the disease. While clinicians are treating COVID-19 patients in isolation rooms, and accommodating home visits and births when possible, properly managing patient care while reducing the risk of exposure for care providers requires tools that enable remote monitoring of vitals.

allow for continuous, non-invasive monitoring of maternal heart rate, fetal heart rate, and uterine activity with a single-use, 48-hour, disposable electrode patch placed on the mother’s abdomen. The patch is designed to be placed on the patient by a clinician only once, unlike traditional elastic belts and sensors that require frequent repositioning.

“Remote monitoring during labor has always provided multiple benefits to expectant mothers, including comfort, mobility, and flexibility. But during the COVID-19 pandemic, the need for mobile solutions during pregnancy is greater than ever,” said Peter Ziese, General Manager, Monitoring & Analytics at Philips. “Philips has been dedicated to providing the best quality care for expectant mothers for more than fifty years. This new solution builds on our commitment to provide integrated continuous monitoring capabilities for high risk pregnancies. With this new patch, clinicians now have access to an innovative tool to help monitor pregnant women during COVID-19, helping to deliver comfort to these mothers during a particularly stressful time.”  

“The fact that the new sensors are disposable and don’t require constant repositioning has been particularly useful for us in the peak of the COVID-19 wave in March and April in Lisbon,” said Prof. Dr. Diogo Ayres-de-Campos, University of Lisbon, and President-Elect of the European Association of Perinatal Medicine (EAPM).

The Philips OB solution consists of the , featuring Philips proprietary Smart Pulse technology, and an obstetrical information management system for continuous data flow to the EMR, which includes:

  • : single-use disposable patch and reusable pod placed on the expectant mother’s abdomen to capture fetal and maternal heart rate, and uterine activity through ECG and EMG signals, without the need for constant repositioning;
  • : provides cableless monitoring with the Avalon Fetal Monitors to give expectant mothers freedom to move during labor, while measuring up to three fetuses. The Avalon CL Wide Range Pod leverages the hospital’s wireless LAN installation to allow mothers to expand the area of ambulation, by extending monitoring of all cableless measurements to the full reach of the WLAN.;
  • : obstetrical surveillance and information management system designed for use from antepartum visit through labor, delivery, and postpartum care. Patient data automatically displays and streams to the electronic medical record (EMR). ISP Revision K in combination with IntelliVue XDS Remote Display functionality offers the ability to control the Fetal Monitor remotely.

The received CE Mark clearance in 2019 and is available in many EU countries [2], as well as Australia, New Zealand and Singapore.

Philips has a comprehensive portfolio of services and solutions which can help to support the delivery of high-quality care to COVID-19 patients. It includes secure, connected and intelligent approaches to diagnosis, treatment and predictive monitoring in the hospital, plus screening, remote patient monitoring and care at home. With healthcare under more pressure than ever before, Philips’ telehealth and AI-enabled data analytics can help support workflows, facilitate remote collaboration and optimize resources. Philips’ COVID-19-related solutions are designed for rapid deployment and scalability. For more information on how Philips is addressing COVID-19 globally, please visit the . 

[1] .

[2] The Avalon Fetal and Maternal Pod and Patch is available across Europe in the Benelux, DACH, UK&I, Nordics, CEE and Iberia markets. 

For more information, please contact:

Kathy O’Reilly

Philips Global Press Office

Tel:

Email:

Twitter:

Silvie Casanova

Philips North America

Tel:

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at .



 

Attachments

EN
12/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips publishes its Annual Report 2025

Philips publishes its Annual Report 2025 February 19, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025. Philips’ Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course. Philips filed the Annual Report 2025 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to f...

 PRESS RELEASE

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI ...

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI coil for its 3.0T MR systems, helping to enhance imaging precision, efficiency and comfort February 12, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems. Designed specifically for pediatric patients, the Snuggle coil has been optimized and validated for use with Philips 3.0T MRI systems, bringing enhanced comfort for children and efficient, high-quality i...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ABN Amro: Miss but strong capital, good set of results / Ahold Delhaize: Strong 4Q25 but no major surprise on FY26 adj. EPS guidance / Alfen: No recovery yet and another transitional year / BAM Group: Preview: 2026 outlook the key item / Econocom: Better REBITA, net debt, but EBIT below, much lower net profit, dividend halved, 2026-28 guidance postponed to “medium term” / Exor: Ferrari 4Q25 and 2026 guidance beat / Gecina: Results and guidance in line, DPS set to grow over 2026-30 / Heineken: No...

Oscar Rodriguez
  • Oscar Rodriguez

PHILIPS: RDOS. 4T’25 Y CAMBIO DE P.O. AL ALZA (ANÁLISIS BANCO SABADELL...

Rdos. 4T’25 vs 4T’24: Ventas: 5.097 M euros (+1,1% vs -0,9% BS(e) y -1,0% consenso); EBITA Aj.: 770 M euros (+13,4% vs +0,6% BS(e) y -1,0% consenso); BDI: 397 M euros (-333 M euros en 2024 vs 275 M euros BS(e) y 276 M euros consenso); Rdos. 2025 vs 2024: Ventas: 17.834 M euros (-1,0% vs -1,6% BS(e) y -1,6% consenso); EBITA Aj.: 2.195 M euros (+5,7% vs +1,5% BS(e) y +1,0% consenso); BDI: 897 M euros (-698 M euros en 2024 vs 775 M euros BS(e) y 776 M euros consenso).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch